Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Hrach AsmerianCenter for Neural Science and Medicine, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurology, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.ORCID 0009-0004-6448-9156
Alexia J DiazCenter for Neural Science and Medicine, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurology, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.ORCID 0009-0004-0830-2799
Hongfei XuDepartments of Physiology and Neurology, University of California, San Francisco School of Medicine, San Francisco, CA, USA.ORCID 0000-0003-1381-2123
Juan A Oses-PrietoDepartment of Pharmaceutical Chemistry, University of California, San Francisco School of Medicine, San Francisco, CA, USA.ORCID 0000-0003-4759-2341
Jacob AlbertsCenter for Neural Science and Medicine, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurology, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.
Barathan GnanabharathiCenter for Neural Science and Medicine, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurology, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.ORCID 0000-0001-9996-0578
Anna M SanetraCenter for Neural Science and Medicine, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurology, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.ORCID 0000-0002-3070-4688
Poulomi DasDepartments of Physiology and Neurology, University of California, San Francisco School of Medicine, San Francisco, CA, USA.
Noah CarrCenter for Neural Science and Medicine, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurology, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.ORCID 0009-0000-7823-6804
Alma L BurlingameDepartment of Pharmaceutical Chemistry, University of California, San Francisco School of Medicine, San Francisco, CA, USA.ORCID 0000-0002-8403-7307
Robert H EdwardsDepartments of Physiology and Neurology, University of California, San Francisco School of Medicine, San Francisco, CA, USA.ORCID 0000-0002-8650-3260
Kätlin SilmCenter for Neural Science and Medicine, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurology, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA.ORCID 0000-0003-3677-0165
Funding
Glutamate Transport into Synaptic VesiclesR01NS129803 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROBERT H EDWARDS · 2023 to 2026
$2.0M
Neurotransmitter CoreleaseR01NS103938 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EDWARDS, ROBERT H · 2017 to 2021
$1.9M
Diversity of Presynaptic Function Among Neuronal PopulationsR01NS138465 · NINDS · CEDARS-SINAI MEDICAL CENTER · PI Katlin Silm · 2025 to 2026
Neuromodulators such as monoamines assure essential brain functions, but relatively little is known about their mechanism of release. While recent work has advanced our knowledge of active zone architecture in dopamine axons, release machinery within the synaptic vesicle (SV) remains poorly understood. Here, we address differences between the release of monoamines and synaptic transmitters by comparing the composition of SVs that contain the vesicular monoamine transporter 2 (VMAT2) versus vesicular glutamate transporter 2 (VGLUT2). Previous work revealed that these SVs differ in frequency dependence, recycling kinetics, and biogenesis. We now find differences in the abundance and isoform expression of many SV protein families and validate these differences in primary neurons and brain tissue. Functional analysis after heterologous expression in hippocampal neurons shows that loss of differentially expressed SCAMP5 selectively impairs the recycling of VGLUT2 SVs, sparing vesicles targeted by VMAT2 in the same neuronal population. These findings provide insights into the molecular diversity of SVs and mechanisms of dopamine release.
Indexed as
Biogenic MonoaminesGlutamic AcidSynaptic VesiclesAnimalsDopamineHippocampusNeuronsRatsVesicular Glutamate Transport Protein 2Vesicular Monoamine Transport ProteinsBiogenic MonoaminesDopamineGlutamic AcidVesicular Glutamate Transport Protein 2Vesicular Monoamine Transport Proteins
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Synaptic vesicles that store monoamines and glutamate differ in protein composition. · full record | Socratic